Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (1761)	5/26/2015 8:31:52 AM
From: Biotech Jim	Respond to of 3559

AMGN's PDUFA date for Repatha is 8/27/2015.

To: Biotech Jim who wrote (1761)	5/28/2015 12:52:51 AM
From: Felix B	Respond to of 3559

Yep the PDFUA dates and ad com meetings for both are known for US but was curious if there are dates out there for the EMA either advisory meeting that Amgen just had or actual decision for REGN. Regarding lawsuit, I believe REGN mentioned in the last CC that they lawsuit will not prevent FDA decision, but could be mistaken as they don't talk much about the law suit. I am curious how pricing will play out, Reuters mentioned 5/10K depending on dose for Praulent and 10K for Amgen's. The lower price point and (possible) head start should help REGN although curious how monthly dosing will effect. As in the case for Eylea, convenient dosing may win out. I thought there was a study with Praulent dosed monthly but it wasn't as effective?